Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR Maintenance in GEP or Esophageal NEC
NCT02409849Phase 2Unknown
- Sponsor
- Peking University
- Start
- Apr 2015
- Primary completion
- Nov 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of octreotide in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), esophageal neuroendocrine carcinoma (ENEC), sponsored by Peking University. Status: unknown.
02
Drugs
octreotide
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)esophageal neuroendocrine carcinoma (ENEC)
Beyond the preview
Go deeper on NCT02409849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409849.